Document is current
Any future updates will be listed below
-
Authors
Rosenberg, Anna
Untersteiner, Helena
Guazzarini, Anna Giulia
Bödenler, Markus
Bruinsma, Jeroen
Buchgraber-Schnalzer, Bianca
Colombo, Matteo
Crutzen, Rik
Diaz, Ana
Fotiadis, Dimitrios I.
Hilberger, Hannes
Huber, Simone
Kaartinen, Nico
Kassiotis, Thomas
Kivipelto, Miia
Lehtisalo, Jenni
Loukas, Vasileios S.
Lötjönen, Jyrki
Pirani, Mattia
Thunborg, Charlotta
Hanke, Sten
Mangialasche, Francesca
Mecocci, Patrizia
Stögmann, Elisabeth
Ngandu, Tiia
,
-
Funding
Funding for this research was provided by:
Horizon 2020 Framework Programme (101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405, 101017405)
Forskningsrådet om Hälsa, Arbetsliv och Välfärd (2023-01125, 2023-01125)
Region Stockholm
Finnish Institute for Health and Welfare
- License Information
-
More Information
Article History
Received: 2 February 2024
Accepted: 3 November 2024
First Online: 21 November 2024
Declarations
:
: The trial has been approved by ethical committees in Austria (Ethics Committee of the Medical University of Vienna, 1392/2022), Finland (Helsinki and Uusimaa Hospital District Ethical Committee, HUS/13675/2022, statement 22/2023), Italy (Regional Ethics Committee—CER Umbria, 27604/23/ESS), and Sweden (Swedish Ethical Review Authority, 2023–05110-02). All participants provided informed consent prior to enrollment.
: Not applicable.
: HU, AG, MB, JB, BBS, RC, AD, DF, HH, SiH, TK, JeL, VL, CT, StH, FM, PM, ES, TN declare that they have no competing interests. AR and MK are Editors of Alzheimer’s Research & Therapy. MC and MP are employed by Innovation2Grow. NK is employed by Kaasa Solution GmbH. JyL is employed by and a stakeholder at Combinostics Ltd.
